期刊文献+

不同浓度沙利度胺对K562细胞凋亡及血管内皮生长因子分泌的影响 被引量:2

Effect of Thalidomide on Apoptosis of K562 Cells and its Vascular Endothelial Growth Factor Secretion
原文传递
导出
摘要 目的研究沙利度胺对人慢性粒细胞白血病急变株K562细胞凋亡及血管内皮生长因子(vascularendothelia growth factor,VEGF)分泌的影响。方法采用不同浓度的沙立度胺(0.5、1.0、2.0 mmol/L)作用于K562细胞24、48、72、96 h,瑞-姬(Wright-Giemsa)染色法观察细胞形态;四甲基偶氮唑盐(methylthiazolyl tetrozolium,MTT)法检测细胞增殖;流式细胞仪膜联蛋白V-异硫氰酸荧光素/碘化丙啶双染法检测凋亡率;琼脂糖凝胶电泳法检测脱氧核糖核酸梯状条带;酶联免疫吸附法检测VEGF浓度。结果培养24、48 h后,沙立度胺对K562细胞生长无抑制作用;作用72 h后,1.0、2.0 mmol/L浓度组开始出现对K562细胞生长的抑制(P<0.001);作用96 h后,0.5 mmol/L浓度组也产生对K562细胞生长的抑制(P<0.001),呈一定的浓度和时间依赖性。沙立度胺处理72 h后,K562细胞出现形态学改变,其体积缩小,出现空泡化,边缘出现突起,染色质浓缩、边集,核固缩、出现凋亡小体。经沙立度胺处理后,流式分析结果显示K562细胞凋亡率增加(P<0.001)。沙立度胺作用72 h后,琼脂糖凝胶电泳可见典型的DNA梯状条带。K562细胞培养48 h后,沙立度胺抑制VEGF的分泌(P<0.001),并且VEGF浓度与凋亡率呈负相关(r=-0.789)。结论沙利度胺抑制K562细胞的增殖,呈一定的浓度和时间依赖性;沙利度胺对K562细胞凋亡有明显诱导作用;沙利度胺抑制K562细胞VEGF的分泌。 Objective To investigate the effect of thalidomide on apoptosis of k562 cells and its vascular endothelial growth factor secretion. Methods K562 cells were cultured in vitro with 0. 5, 1.0, and 2. 0 mmol/L thalidomide for 24, 48, 72, and 96 hours. Morphology of the K562 cells was ohserved by the Wright-Giemsa staining method. Methylthiazolyl tetrozolium (MTI) assay was used to determine the cell growth. The rate of apoptosis was analyzed by flow cytometry (FCM) with annexin V-fluoreseein isothiocyanate/propidium iodide (AnnexinV-FITC/PI) double-staining method. Agarose gel electrophoresis was used to detected Deoxyribonucleic acid Ladder (DNA Ladder). The concentration of VEGF was quantified by the enzyme-linked immunosorbent assay (ELISA). Results Cultured for 24 or 48 hours, thalidomide had no effect on the proliferation of the K562 cells. But after cultured for 72 hours, thalidomide began to inhibit the growth of the K562 cells at the concentration of 1.0 and 2.0 mmol/L (P% 0. 001). After cultured for 96 hours, the proliferation of the K562 cells was inhibited too at the concentration of 0. 5 mmol/L thalidomide (P^0. 001). Thus, thalidomide inhibited the growth of the K562 cells with a dose-and time dependent manner to some extent. After exposure to thalidomide for 72 hours, K562 cells underwent typical morphological changes of apoptosis such as vaculization, the budding of cytoplasm, chromatin condensation, margination, shrunken nucleus and apoptotic body. The results of flow cytometry showed that thalidomide could obviously increase the rates of the apoptosis of K562 cells (P%0. 001). After treated with thalidomide for 72 hours,DNA was extracted for Agarose gel electrophoresis and typical DNA ladder strips were observed. The secretion of VEGF was inhibited when exposure to thalidomide for 48 hours (P〈0. 001), and there was negative correlation between VEGF concentrations and apoptotic rates(r=- 0. 789). Conclusions Thalidomide could inhibite the growth of the K562 cells with a dose-and time-dependent manner to some extent. Thalidomide could obviously induce the apoptosis of the K562 ceils and inhibit its secretion of VEGF.
出处 《华西医学》 CAS 2011年第9期1298-1302,共5页 West China Medical Journal
关键词 慢性粒细胞白血病 沙利度胺 凋亡 K562细胞 血管内皮生长因子 Chronic myeloid leukemia Thalidomide Apoptosis K562 cells Vascular endothelialgrowth factor
  • 相关文献

参考文献16

  • 1Katouli AA, Komarova NL. Optimizing combination therapies with existing and future CML drugs[J]. Plos One, 2010, 5(8): 1-12.
  • 2Hehlmann R, Hochhous A, Baccarani M. Chronic myeloid leukaemia[J]. Lancet, 2007, 370(9584): 342-350.
  • 3Venepalli N, Rezvani K, Mielke S, et al. Role of allcrSCT for CML in 2010[J]. Bone Marrow Transpl, 2010, 45 (11): 1579-1586.
  • 4Volpe G, Panuzzo C, Ulisciani S, et al. Imatinib resistance in CML[J].Cancer Lett, 2009, 274(1): 1-9.
  • 5Quentmeier H, Eberth S, Romani J, et al. BCR-ABL1-independent PI3 Kinase activation causing imatinib-resistance [J]. J HematolOncol, 2011, 4(1): 6-15.
  • 6韩丽英,陈枫,张玉高.大蒜素对K_(562)细胞增殖抑制和诱导凋亡作用的实验研究[J].临床血液学杂志,2006,19(4):239-240. 被引量:5
  • 7韩丽英,陈枫,张玉高.他莫昔芬诱导K562细胞凋亡的实验研究[J].白血病.淋巴瘤,2006,15(1):13-15. 被引量:1
  • 8Du G J, Lin HH, Xu QT. et al. Thalidomide inhibits growth of tumors through COX-2 degradation independent of antiangiogenesis[J]. Vasc Pharmacol, 2005, 43(2) : 112-119.
  • 9Lima LM, Manssour Fraga CA, Gonc.alves Koatz VL, et al. Thalidomide and analogs as anti-Inflammatory and immunomodulator drug candidates [J]. Anti-Inflammatory & Anti-Aller, 2006, 5(1):79-95.
  • 10Sissung TM, Thordardottir S, Gardner ER, et al. Current Status of Thalidomide and CC-5013 in the treatment of metastatic prostate cancer[J]. Anti-Cancer Agent Me, 2009, 9(10): 1058-1069.

二级参考文献26

  • 1李敏,石晓翮,王鹂,闽吉梅,崔景荣.大蒜提取物Z-ajoene对U937细胞增殖抑制作用机制的研究[J].中国药理学通报,2004,20(6):688-693. 被引量:11
  • 2Hoeijmakers J H.Genome maintenance mechanisms for preventing cancer[J].Nature,2001,411(6835):366-374.
  • 3D'Amato RJ,Loughnan MS,Flynn E,et al.Thalidomide is an inhibitor of angiogenesis[J].Proc Natl Acad Sci USA,1994,91 (9):4082-4085.
  • 4Kerst JM,Bex A,Mallo H,et al.Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiothetapy to bone and/or soft tissue metastasis:a phase Ⅱ study[J].Cancer Immunol Immunother,2005,54(9):926-931.
  • 5Dmoszynska A,Podhorecka M,Manko J,et al.The influence of thalidomide therapy on cytokine secretion,immunophenotype,BCL-2 expression and microvessel density in patients with resistant or relapsed multiple myeloma[J].Neoplasm,2005,52(2):175-181.
  • 6Invernizzi R,Travaglino E,De Amici M,et al.Thalidomide treatment reduces apoptosis levels in bone marrow cells from patients with myelodysplastic syndromes[J].Leukemia Res,2005,29 (6):641-647.
  • 7Grzasko N,Dmoszynska A,Hus M,et al.Stimulation of erythropoiesis by thalidomide in multiple myeloma patients:its influence on FasL,TRAIL and their receptors on erythroblasts[J].Haematologica,2006,91(3):386-389.
  • 8Settles B,Stevenson A,Wilson K.Down-regulation of cell adhesion molecules LFA-1 and ICAM -1 after in vitro treatment with the antiTNF-alpha agent thalidomide[J].Cell Mol Biol (Noisy-le-grand),2001,47(7):1105-1114.
  • 9Glasmacher A,Hahn C,Hoffmann F,et al.A systematic review of phase-Ⅱ trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma[J].Br J Haematol,2006,132 (5):584-593.
  • 10Rajkumar SV,Blood E,Vesole D,Fonseca R,et al.Phase Ⅲ clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma:a clinical trial coordinated by the Eastern Cooperative Oncology Group[J].J Clin Oncol,2006,24(3):431-436.

共引文献7

同被引文献27

  • 1赵丹,周云,罗执芬.低剂量替尼泊苷联合沙利度胺对人胃癌移植瘤的抑制作用[J].郑州大学学报(医学版),2009,44(5):951-954. 被引量:1
  • 2杨云,张王刚,陈银霞,曹星梅,何爱丽,杨惠云,田玮.沙利度胺对人外周血单个核细胞免疫正调控作用[J].中国实验血液学杂志,2006,14(6):1172-1177. 被引量:9
  • 3孙立荣,于宏,庞秀英,李学荣,卢愿,宋爱琴,仲任,赵艳霞.干扰素α-2b对人类早幼粒白血病细胞株HL-60细胞的抑制增殖与促进凋亡的作用(英文)[J].中国组织工程研究与临床康复,2007,11(50):10217-10220. 被引量:1
  • 4Steins MB, Padr6 T, Bieker R, et al. Efficacy and safety of thalid- omide in patients with acute myeloid leukemia[J]. Blood, 2002, 99(3): 834-839.
  • 5Hill NO, Pardue A, Khan A, et al. Clinical trials of human leuko- cyte interferon in malignancy [J]. Tex Rep Biol Med, 1981/ 1982, 41: 634-640.
  • 6Arellano ML, Langston A, Winton E, et al. Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience [J]. Biol Blood Marrow Transplant, 2007, 13 (1): 116-123.
  • 7McSweeney EN, Worman CP, Tsakona CP, et al. Low-dose recombinant alfa-2a-interferon: a feasible maintenance therapy in acute myeloid leukaemia in the older patient [J]. ActaHaematol, 1993, 89( 1 ): 1-5.
  • 8Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis [J]. Oncogene, 2003, 22 (53): 8590- 8607.
  • 9Sharpe JC, Arnoult D, Youle RJ. Control of mitochondrial permeability by Bel- 2 family members [J]. Biochim Biophys Acta, 2004, 1644(2/3): 107-113.
  • 10Cryns V, Yuan J. Protease to die for[J]. Genes Dev, 1998, 12 (11): 1551-1570.

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部